COMPLICATIONS OF MICROWAVE ABLATION
RISK AND MANAGEMENT
Understanding complications honestly — their frequency, what causes them, and how they are managed — is essential to informed consent. MWA is generally safe, but like any invasive procedure, it carries real risks that every patient should understand before proceeding.
analyticsAt a Glance
- check_circleMajor complications in 2–8% of procedures — lower than surgical alternatives
- check_circleMost serious complication: bleeding (1–3%); usually managed without surgery
- check_circleLung ablation pneumothorax 15–30%; intervention needed in 5–10%
- check_circleProcedural mortality <0.5% at experienced centres
Overall Safety: Putting Complications in Context
Microwave ablation has an excellent overall safety record — major complications occur substantially less frequently than equivalent surgical procedures. Understanding the complication profile requires comparing it to the alternatives, not evaluating it in isolation.
“Major complications from liver MWA occur in 2–4% of procedures. Major complications from hepatic resection occur in 15–30%. The comparison matters when evaluating risk.”
Complication Classification
Complications are classified using the Society of Interventional Radiology (SIR) grading system: Minor complications (grades A–B) require minimal treatment and have no lasting consequences. Major complications (grades C–F) require hospitalization, additional interventions, permanent effects, or can be life-threatening. Published series report major complication rates and mortality separately.
Centre Experience Matters
Complication rates are strongly linked to operator experience and annual procedure volume. High-volume centres (>100 ablations/year) consistently report lower major complication rates than low-volume centres. Choosing an experienced centre is the single most important risk-reduction strategy available to patients.
Complications by Type, Organ, and Frequency
Published complication rates from major MWA series. Rates vary by organ, tumour size, and centre experience.
| Complication | Liver MWA | Lung MWA | Kidney MWA | Severity |
|---|---|---|---|---|
| Post-ablation syndrome (fever/fatigue) | 50–80% | 40–70% | 30–60% | Minor — expected, self-limited |
| Haemorrhage requiring intervention | 1–3% | 1–2% | 2–4% | Major — usually embolisation, rarely surgery |
| Pneumothorax (any grade) | N/A | 15–30% | N/A | Minor–Major — chest drain in 5–10% |
| Bile duct injury / biloma | 1–3% | N/A | N/A | Major — drainage procedure often needed |
| Thermal injury to adjacent bowel | 0.2–1% | N/A | 0.5–1% | Major — surgery required if perforation |
| Pleural effusion | 3–8% | 5–15% | N/A | Minor–Major — drainage if large/symptomatic |
| Hepatic abscess / infection | 1–2% | N/A | 0.5–1% | Major — IV antibiotics; drainage if needed |
| Ureteral or collecting system injury | N/A | N/A | 1–3% | Major — stenting or drainage may be needed |
| Tumour seeding along tract | 0.1–0.5% | 0.2–0.5% | 0.1–0.3% | Major (delayed) — local treatment of seeded lesion |
| Skin burn at antenna site | <1% | <1% | <1% | Minor — wound care |
| Procedure-related death | <0.3% | <0.5% | <0.3% | Fatal — rare at experienced centres |
Major Complications in Detail
Each major complication has specific characteristics, risk factors, and management approaches that patients benefit from understanding before the procedure.
Haemorrhage (Bleeding)
The most common serious complication. Blood vessels in or near the tumour may be disrupted during antenna placement or during ablation. Most bleeding is minor and self-limited; significant bleeding requiring intervention occurs in 1–3% of cases. Management: observation for minor bleeding; transcatheter arterial embolisation (a catheter procedure, not surgery) for significant bleeding; surgical exploration rarely needed.
Bile Duct Injury and Biloma (Liver MWA)
Thermal injury to bile ducts adjacent to the ablation zone can cause bile leakage into the liver (biloma) or bile duct stricture. Risk is highest for tumours close to major bile ducts. Biloma may present as fever, pain, and elevated liver enzymes days to weeks after the procedure. Management: percutaneous drainage under imaging guidance; biliary stenting for strictures.
Pneumothorax (Lung MWA)
Air entering the pleural space during or after antenna placement through the chest wall. Occurs in 15–30% of lung MWA procedures. Small pneumothoraces resolve spontaneously over hours to days. Significant pneumothorax causing breathlessness requires chest drain insertion (small tube placed at the bedside under local anaesthetic) and typically resolves within 24–48 hours.
Thermal Injury to Adjacent Structures
Bowel, gallbladder, common bile duct, ureter, diaphragm, and other structures adjacent to the ablation zone can be heated and injured. Risk is minimised by hydrodissection (injecting fluid between tumour and adjacent structure before ablation to create a thermal buffer). Bowel perforation from thermal injury requires surgery; less severe injuries may be managed conservatively.
Tumour Seeding
Tumour cells can occasionally be deposited along the antenna tract during withdrawal, leading to a nodule at the skin or along the tract weeks to months later. Rare (<0.5%) but more likely with HCC and certain histologies. Mitigated by tract ablation during antenna withdrawal (energy delivered along the entire needle track as it is removed).
How Risks Are Minimised
Experienced interventional oncology centres implement multiple strategies to minimise complication rates. Understanding these helps patients evaluate centre quality.
Operator Experience and Volume
The strongest predictor of low complication rates is operator experience. High-volume centres with dedicated interventional oncology programmes and annual volumes >50–100 ablations consistently report lower major complication rates. Ask the centre how many MWA procedures they perform annually.
Precise Image Guidance
Real-time CT or ultrasound guidance ensures the antenna is placed accurately into the tumour and not into adjacent critical structures. High-resolution imaging, experienced guidance technique, and verification at multiple points before ablation reduces misplacement complications.
Hydrodissection for Adjacent Structures
When the tumour is close to bowel, ureter, or other heat-sensitive structures, saline or diluted contrast is injected between the tumour and the structure before ablation. This fluid acts as a thermal barrier, protecting the adjacent tissue. Critical technique for renal and some liver ablations near bowel.
Pre-Procedure Patient Optimisation
Correcting coagulopathy before the procedure (vitamin K for warfarin users, platelet transfusion for severe thrombocytopenia, DDAVP for renal impairment), antibiotic prophylaxis for infection-prone patients (biliary disease, prior biliary intervention), and careful patient selection reduce complication rates.
Post-Procedure Monitoring Protocol
Structured post-procedure observation with regular vital signs, early imaging if symptoms develop, and clear patient-facing instructions about warning signs allow early detection and management of complications before they become serious. Ask your centre about their post-procedure monitoring protocol.
Related Treatments & Resources
Explore the full microwave ablation knowledge base.
- What to Expect During and After Microwave Ablation
- What Is Microwave Ablation? A Patient Introduction
- Microwave Ablation for Liver Cancer (HCC): Evidence and Outcomes
- Microwave Ablation for Lung Cancer: NSCLC and Pulmonary Metastases
- Microwave Ablation for Kidney Cancer (RCC)
- Microwave Ablation — Full Treatment Page
Frequently Asked Questions
Common questions about microwave ablation complications.
About Specific Complications
How will I know if I have a bile duct injury after liver ablation?
Bile duct injury typically presents as persistent or worsening pain in the right upper abdomen, fever developing or persisting beyond 5–7 days post-procedure, nausea, and occasionally jaundice (yellowing of skin or eyes). Blood tests typically show elevated liver enzymes and bilirubin. Any of these symptoms appearing or worsening after the first few days should prompt medical contact.
If I have a pneumothorax after lung ablation, how will it be treated?
Small pneumothoraces (less than 20% of lung volume) often resolve spontaneously with observation and supplemental oxygen. Larger pneumothoraces, or those causing breathlessness, are treated by inserting a small chest drain — a thin tube placed through the chest wall under local anaesthetic at the bedside. Most patients with drain insertion are discharged the next day once the lung has re-expanded. Rarely, a persistent air leak requires more prolonged drainage or surgical intervention.
What is tumour seeding and how worried should I be?
Tumour seeding — deposition of tumour cells along the ablation antenna tract — is rare (<0.5%) and more likely with certain tumour types. Experienced operators perform "tract ablation" (delivering energy along the full needle track during withdrawal) to destroy any cells deposited. If seeding does occur, the resulting nodule is usually small and treatable with a further ablation session. It is a known risk worth being aware of, but should not be a reason to avoid ablation when the procedure is otherwise appropriate.
Comparative Risk
How does MWA complication risk compare to surgery?
For liver tumours requiring hepatic resection, major surgical complication rates are 15–30%; mortality 1–3% at experienced centres. For MWA of comparable liver tumours, major complication rates are 2–4%; mortality <0.3%. The absolute risk reduction from choosing MWA over surgery is substantial — this is a major reason why ablation has become the preferred treatment for patients with small HCC who are not optimal surgical candidates.
How does CancerFax help me find a low-complication-rate centre?
CancerFax identifies centres with high procedure volumes, published outcome data, and dedicated interventional oncology programmes. Annual procedure volume and major complication rates are specific questions we ask on your behalf. We prioritise experienced centres in China, India, Europe, and the US based on your tumour type, location, and clinical profile.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Want to Understand Complication Risk for Your Specific Case?
Upload your imaging and medical records. Our team will review your specific tumour location and characteristics to provide an honest risk assessment and identify the most experienced centres for your case.
For informational purposes only. Complication risk depends heavily on individual patient and tumour factors. Always discuss your specific risk with your treating interventional radiologist.